NICE Issues Final Guidance on Amarin’s Vazkepa (icosapent ethyl) for the Treatment of Cardiovascular Disease
- NICE has issued its final guidance recommending Vazkepa for reimbursement & use in the NHS in England and Wales to reduce the risk of major CV events in high-risk statin-treated patients with eCVD who have elevated triglycerides & eCVD. The product will be available on all local NHS formularies within 90 & 60 days
- Final guidance also provides additional evidence that Amarin is successfully implementing its EU growth strategy & maximize the product's international revenue outside of the US. The product is expected to be available across a territory in the coming mos.
- Vazkepa is expected to be available in ~6 EU countries in 2022. The company will secure pricing decisions in ~8 countries & advance the reimbursement conversations in other EU markets
Ref: GlobalNeweswire | Image: Amarin
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.